BioVie is a clinical-stage company. Co. is engaged in the discovery, development, and commercialization of drug therapies. Co. is focused on developing and commercializing BIV201 (continuous infusion terlipressin), an approach to the treatment of ascites due to chronic liver cirrhosis. Co.'s therapy BIV201 is based on a drug that is approved in several countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. The BIVI stock yearly return is shown above.
The yearly return on the BIVI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BIVI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|